Robert Whitfield MD covers what doctors need to watch when patients use GLP-1 receptor agonists for weight loss: check for nausea, vomiting, and diarrhea; monitor diabetes control; and pause the peptides around surgery because recovery gets complicated. Clear communication about compliance matters.
For us. We don't much like you've mentioned, microdosing makes perfect sense to us. And when I have somebody come in who's been on any of the GLP1s, we gotta do a symptom inventory. Did you have nausea, vomiting, diarrhea, abdominal pain? Are you exacerbating anything else? If you had diabetes, is it under control? Gone, Getting better. What's it doing? I think it adds another layer now to any practitioners. Basically, symptom survey that you have to do all the time. I actually hold if we're going to do it in relationship to a fat transfer. And then people ask me, do I put people on peptides a lot in the recovery phase. And I don't for a number of reasons. Mostly surgery is very complicated in terms of compliance and I already have a very specific program to run. So once you get them further out, it becomes more acceptable to do that. And you can discuss like your compliance with specific peptide therapy and what it requires on the patient side. So everybody understands from your perspective. Yeah.
